Get started
Author

Yoshiaki Marumo

ORCID: 0009-0003-6326-4994
Observed ORCID: 0009-0003-6326-4994
OpenAlex ID: A5052201218
Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome
2023 · Ayaka Maeda, Naomi Tsuchida, et al. · Lara D. Veeken · 43
Exophiala dermatitidis Fungemia Diagnosed Using Time-of-flight Mass Spectrometry during Chemotherapy for Malignant Lymphoma and Successful Treatment with Voriconazole
2019 · Takashi Yoshida, Takuto Tachita, et al. · Internal Medicine · 14
PDF
Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myeloma
2023 · Yoko Nakanishi, Yoshiaki Marumo, et al. · International Journal of Hematology · 10
Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation
2019 · Hirokazu Sasaki, Sachiko Mitani, et al. · International Journal of Hematology · 10
Immunosuppressive Effects of Multiple Myeloma‐Derived Extracellular Vesicles Through T Cell Exhaustion
2025 · Shinya Hagiwara, Masaki Ri, et al. · Cancer Science · 8
PDF
Autoimmune Hemolytic Anemia Obscured by the Obstructive Jaundice Associated with IgG4-related Sclerosing Cholangitis in a Patient with Type 1 Autoimmune Pancreatitis: A Case Report and Review of the Literature
2017 · Michihiro Yoshida, Yoshiaki Marumo, et al. · Internal Medicine · 7
PDF
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide‐treated myeloma patients
2022 · Arisa Asano, Masaki Ri, et al. · Hematological Oncology · 6
Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma
2019 · Takashi Yoshida, Masaki Ri, et al. · International Journal of Hematology · 6
Diagnosis of a SMARCA4 ‐deficient undifferentiated tumor using multigene panel testing: A case report
2023 · Yoshiaki Marumo, Takashi Yoshida, et al. · Clinical Case Reports · 4
Newly diagnosed follicular lymphoma during pembrolizumab treatment for lung cancer
2021 · Yoshiaki Marumo, Shigeru Kusumoto, et al. · International Journal of Hematology · 4
Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution
2024 · Naohiro Matsunaga, Tomotaka Suzuki, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma
2023 · Tomotaka Suzuki, Shigeru Kusumoto, et al. · International Journal of Hematology · 3
PDF
Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma
2025 · Toru Ebina, Masaki Ri, et al. · Cancer Science · 2
PDF
Prevalence of CCR7‐Positive CD8 T Cells as a Prognostic Factor in B‐Cell Maturation Antigen ‐Targeted Chimeric Antigen Receptor T Cell Therapy
2025 · Yoshiaki Marumo, Masaki Ri, et al. · eJHaem · 2
PDF
Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia
2023 · Tomotaka Suzuki, Shigeru Kusumoto, et al. · Cancer Medicine · 2
PDF
Severe and/or prolonged COVID-19 in hematologic diseases: clinical implications before and during the omicron era
2025 · Akinao Okamoto, Masahiro Yoshida, et al. · Frontiers in Oncology · 1
PDF
Cardiac Glycosides Induce Immunogenic Changes in Myeloma Cells and Enhance the Efficacy of Monoclonal and Bispecific Antibody Therapy
2024 · Tomoyuki Nakamura, Masaki Ri, et al. · Blood · 1
PDF
Combined Effects of Severe Immunocompromise and Prolonged Virus Shedding on Within-Host SARS-CoV-2 Evolution in COVID-19
2026 · Yuichiro Hirata, Kenichiro Takahashi, et al. · medRxiv
Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
2024 · Yoshiaki Marumo, Masaki Ri, et al. · Blood
Targeting Overexpressed IDO on Stromal Cells As a Potential Therapeutic Strategy in Multiple Myeloma
2024 · Toru Ebina, Masaki Ri, et al. · Blood
PDF
P820: Potential Immunosuppressive Effect of Extracellular Vesicles From Patients With Multiple Myeloma
2023 · Shinya Hagiwara, Masaki Ri, et al. · HemaSphere
Case report: Genomic analysis of a therapy-related chronic myelomonocytic leukemia with KMT2A rearrangement that progressed to acute myeloid leukemia with acute promyelocytic leukemia-like features
2023 · Tomotaka Suzuki, Rui Yokomori, et al. · Frontiers in Oncology
PDF
Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan
2023 · Yoshiaki Marumo, Takashi Yoshida, et al. · Clinical and Experimental Vaccine Research
PDF
Application of the Plan-Do-Check-Act Cycle for Managing Immune-Related Adverse Events
2021 · Satoshi Hibi, Yuko Shirokawa, et al. · Journal of Analytical Oncology
PDF
P37-7 Investigation of discarded anticancer agents after preparation in Nagoya Memorial Hospital
2021 · Satoshi Hibi, Megumi Kabeya, et al. · Annals of Oncology
Works count: 28
Citation count: 126
H-index: 6
I10-index: 4
Year
Topic
Type